IL22 and neoplasm: Notably, the benefit of focused short-term application of IL-11 or IL-22 in acute disorders, such as APAP-induced ALI, should likely outweigh the inherent danger of these cytokines to promote in the long run tumor growth (74, 86, 118), which has been detected for IL-22 and hepatocellular carcinoma patients (118–120).